OMER Omeros Corporation

13.72
-0.32  -2%
Previous Close 14.04
Open 14.05
Price To Book -7.54
Market Cap 672407733
Shares 49,009,310
Volume 263,239
Short Ratio
Av. Daily Volume 635,880

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation announced January 2, 2018.
OMS721
Hematopoietic stem cell-associated TMA (HSCT-TMA)
Phase 3 trial enrollment initiated February 2018. Phase 2 data released October 1, 2018 showed only marginal improvement compared with placebo.
OMS721
IgA nephropathy
Phase 2 data released October 2016.
OMS721
Kidney disorders
Approved June 2, 2014.
Omidria
Cataract surgery
Phase 3 enrollment has opened - noted March 16, 2017.
OMS721
Atypical hemolytic uremic syndrome (aHUS)
Phase 1 trial initiation announced July 17, 2018.
OMS527
Nicotine Addiction

Latest News

  1. Why Omeros Stock Jumped Today
  2. Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA
  3. Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors
  4. Can We See Significant Insider Ownership On The Omeros Corporation (NASDAQ:OMER) Share Register?
  5. Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data
  6. Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
  7. Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018
  8. Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics — Discovering Underlying Factors of Influence
  9. Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy
  10. Omeros Announces Research Collaboration with University of Cambridge
  11. Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
  12. Omeros Announces Additions to Senior Management Team
  13. Edited Transcript of OMER earnings conference call or presentation 9-Nov-18 1:30pm GMT
  14. New Research Coverage Highlights Omeros, Apple, Bio-Rad Laboratories, Cott, Darling Ingredients, and Osisko Gold Royalties — Consolidated Revenues, Company Growth, and Expectations for 2018
  15. Does Omeros Corporation’s (NASDAQ:OMER) CEO Salary Reflect Performance?
  16. Here's Why Omeros Corporation Fell as Much as 24.5% Today
  17. The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall
  18. Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023
  19. Today's Research Reports on Trending Tickers: Omeros and Spectrum Pharmaceuticals
  20. Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates